|
DALLAS, Nov. 3, 2009 (GLOBE NEWSWIRE) InvestorSoup.com announces an investment report featuring Avanir Pharmaceuticals Inc. (Nasdaq:AVNR). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Avanir Pharmaceuticals Inc. (Nasdaq:AVNR) should be of particular interest to other drug companies: Brystol-Myers Squibb Co. (NYSE:BMY), Eli Lilly & Co. (NYSE:LLY), GlaxoSmithKline Plc. (NYSE:GSK) and Amgen Inc. (Nasdaq:AMGN).
It is available at: http://www.investorsoup.com/lp/AVNR
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Avanir Pharmaceuticals Inc. (AVNR) is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company's product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in phase III clinical development for the treatment of pseudobulbar affect and diabetic peripheral neuropathic pain.
In the report, the analyst notes:
"AVNR in mid-October announced detailed results from the confirmatory double-blind phase III STAR trial evaluating two doses of the investigational drug Zenvia(TM) (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study, Zenvia 30/10 mg and 20/10 mg met the primary efficacy endpoint by reducing PBA episode rates.
"The fundamental outlook for the pharmaceuticals sub-industry for the next 12 months is neutral. Several analysts forecast a modest sales decline in 2009, with volume restricted by less favorable foreign exchange, generic erosion in patent-expired drugs, slow new product flow, and weakness in the overall economy. Many also think the sector faces tougher political and regulatory environments, including proposed drug price discounting in both the Medicare and Medicaid programs. However, sector EPS should show low single digit growth helped by cost restructurings and common share buybacks."
To read the entire report visit: http://www.investorsoup.com/lp/AVNR
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.
CONTACT: InvestorSoup.com
Jeffrey Brown, Editor
(469)-252-3505
info@investorsoup.com
|
